Boulanger-Rostowsky L, Fayet H, Benmoussa N, Ferrandi J
EPSDM, Service du Docteur Talgorn, Secteur 51G02, 56, avenue du Général Sarrail, 51022 Chalons-en-Champagne cedex, France.
Encephale. 2004 Mar-Apr;30(2):153-5. doi: 10.1016/s0013-7006(04)95426-7.
Zolpidem is a sedative and hypnotic drug belonging to imidazopyridine family. Zolpidem facilitates GABAA function more selectively than benzodiazepines, and produces a selective hypnotic effect. In comparison with benzodiazepines this mechanism could be reduce liability to induce dependence. Recently, some cases of zolpidem abuse and dependence have been published. The Authors report 2 cases of addiction to high dose of zolpidem and compare them with others described in the literature. Both patients had been reknown drug addicts before their first prescription of zolpidem and a borderline personality disorder was diagnosed. The patients rapidly developed over consumption and dependence of the molecule, when taking doses as high as 240 and 400 mg daily. To get zolpidem, one patient falsifies prescriptions. They don't suffer from the sedative effects while searching for anxiolytic and stimulating effects. They were also dysarthric, confused, high energy for mental and physical activity. The cases of zolpidem abuse and dependence in the literature describe these symptoms and others such as losing sense of orientation in time and space, amnesia and visual hallucinations. The most typical withdrawal symptom is high levels of anxiety. Moreover, one patient presents an epileptic seizure whereas the other display a severe psychiatric complication such a psychosis. In the literature, withdrawal was accompanied by confusion, suicidal ideas, nausea, vomiting, sweat, tremors, tachycardia and insomnia rebound. The epileptic seizures are described but acute psychosis complication is rare. Pharmacological hypotheses are described. The effects of zolpidem on GABAA receptor gene expression are consistent with the reduced tolerance liability of this drug as well as with other ability to induce both physical dependence and withdrawal syndrome. Through the review of the literature, the Authors noted that 50% of the cases of dependence on zolpidem are drug addicts, therefore concluding that drug addicts are more likely to become dependent on zolpidem.
唑吡坦是一种属于咪唑吡啶类的镇静催眠药。唑吡坦比苯二氮䓬类药物更具选择性地促进γ-氨基丁酸A型(GABAA)受体的功能,并产生选择性催眠作用。与苯二氮䓬类药物相比,这种作用机制可能会降低产生依赖性的倾向。最近,已有一些唑吡坦滥用和依赖的病例报道。作者报告了2例高剂量唑吡坦成瘾病例,并将其与文献中描述的其他病例进行比较。两名患者在首次开具唑吡坦处方之前就已是知名的药物成瘾者,且均被诊断为边缘型人格障碍。患者在每日服用高达240毫克和400毫克剂量时,迅速出现了对该药物的过量服用和依赖。为获取唑吡坦,一名患者伪造处方。他们在寻求抗焦虑和刺激作用时并未出现镇静作用。他们还存在构音障碍、意识模糊、精神和身体活动精力充沛。文献中唑吡坦滥用和依赖的病例描述了这些症状以及其他症状,如时空定向障碍、失忆和视幻觉。最典型的戒断症状是高度焦虑。此外,一名患者出现癫痫发作,而另一名患者出现了严重的精神并发症,如精神病。在文献中,戒断伴有意识模糊、自杀念头、恶心、呕吐、出汗、震颤、心动过速和失眠反弹。癫痫发作有描述,但急性精神病并发症较为罕见。文中描述了药理学假说。唑吡坦对GABAA受体基因表达的影响与该药物耐受性降低的倾向以及诱导身体依赖和戒断综合征的其他能力相一致。通过文献回顾,作者指出50%的唑吡坦依赖病例是药物成瘾者,因此得出结论,药物成瘾者更有可能对唑吡坦产生依赖。